Ventures

Crainio pioneers intracranial pressure (ICP) monitoring, for assessing traumatic brain injuries (TBI) without invasive procedures. Traditional methods involve drilling into the skull, posing risks. Crainio's method uses a forehead probe and a technique called photoplethysmography to measure pulse signals. This gives real-time estimates of ICP without invasive procedures. With TBI being a leading cause of death and disability, Crainio's innovation will potentially revolutionize TBI management.

Polynerve is a cutting-edge solution for repairing nerve injuries, offering a better alternative to traditional methods like autografting. Its unique design helps nerves grow in the right direction, reducing complications and surgical time. This absorbable option improves patient recovery and simplifies surgery for healthcare providers, making it a game-changer in nerve repair procedures.

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Revadix is a pioneering biotech venture focused on transforming the treatment of atrial fibrillation (AF), a common heart rhythm disorder. The company is developing AM-001, a novel therapy that targets the EPAC-1 protein, aiming to restore normal heart rhythm and offer a curative solution rather than just symptom management. Revadix’s approach promises to improve patient outcomes with fewer side effects and better long-term health results. Supported by NLC Health Ventures, the company is advancing AM-001 towards clinical trials, with the potential to revolutionize cardiovascular care.

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.